Molecular Psychiatry

Molecular Psychiatry is a leading international journal dedicated to elucidating the biological mechanisms underlying psychiatric disorders and their treatment. Published by Springer Nature, the journal has established itself as a premier outlet for high-impact research, holding a 2026 Impact Factor of 10.400 and consistently ranking in the JCR Q1 quartile, reflecting its exceptional influence and citation frequency in the fields of neuroscience and psychiatry. The journal’s scope encompasses a broad spectrum of molecular, cellular, and systems-level investigations, with a strong emphasis on translational research that bridges basic neuroscience and clinical application. Core topics include neurogenetics, epigenetics, neuroimaging, neuroinflammation, synaptic plasticity, and the molecular pharmacology of psychotropic drugs. It publishes original research articles, comprehensive reviews, and rapid communications, alongside editorials and commentaries that provide critical perspectives on emerging findings. The target audience includes academic researchers, clinical psychiatrists, neuroscientists, geneticists, and pharmacologists seeking cutting-edge insights into the pathophysiology of conditions such as major depressive disorder, schizophrenia, bipolar disorder, autism spectrum disorders, and anxiety. A notable feature is its hybrid open access model, allowing authors to choose gold open access for global dissemination, while maintaining rigorous peer review standards. Molecular Psychiatry’s consistent Q1 standing and high impact factor underscore its role as a top-tier resource for advancing the molecular understanding of mental illness and informing future therapeutic strategies.